Inovio announces that its INO-5401 combination therapy extends progression-free survival in Phase 1/2 clinical trials treating GBM

Today, Inovio Pharmaceuticals(http:// announcedthat it is working on T-cell activation immunotherapy INO-5401, which is composed of immunoactive agent INO-9012, Libtayo (cemiplimab) Combined therapies, in the treatment of newly diagnosed glioblastoma (GBM) patients in phase 1/2 clinicaltrial(http://, resulted in 80% of patients with methylated MGMT gene reached 6 months of progression-free survival (PFS)INO-5401 is a highly optimizedsynthetic(http://DNA immunotherapy developed by Inovio that encodes a variety of cancer antigens, including hTERT, WT1, and PSMA, designed to activate T-cells in a wide range of human cancer patientsINO-5401 has the potential to be an effective cancer immunotherapy that can be used in combination with checkpoint inhibitorsPreviously, the U.SNational Cancer Institute has listed hTERT, WT1, and PSMA as important cancer antigens that are overexpressed in a variety of cancers and often mutate, targeting these antigens as potentially effective in treating cancer patientsINO-9012 is an immunoactant developed by Inovio that encodes IL-12A total of 52 newly diagnosed GBM patients participated in the Phase 1/2 clinical trial, which was designed to assess the safety, immunogenicity, and initial efficacy of combination therapies made up of INO-5401, INO-9012, and Libtayo in the treatment of GBM patientsInterim data from the trial showed that the combination therapy enabled 80 percent of patients carrying the methylated MGMT gene to reach 6 months of PFS and 75 percent of patients carrying the non-methylated MGMT gene to 6 months of PFS